ESTRO 2024 - Abstract Book

S1051

Clinical - Gynaecology

ESTRO 2024

After surgery, all patients received adjuvant radiotherapy: EBRT (217), EBRT + sequential boost (45), EBRT + concomitant boost (304), EBRT + IRT (772), IRT (510).

Patients were divided into three risk groups for a total of 124 low-risk, 1140 intermediate-risk, and 576 high risk.

About local relapse in each risk category according to radiation treatments, we observed no events for the patients of low risk class. For intermediate risk class multivariate analysis demonstrated a 2.5-fold increased risk for those patients receiving IRT alone. At 5-year the probability of don’t have distant metastasis was 83.4% (95%CI: 81.2-85.6) for the entire population of patients. In the low risk class the probability of no-metastasis was 94.1% (95%CI: 89.4-98.8), in the intermediate risk class was 86.4% (95%CI: 83.9-88.9), in the high risk class was 74.1% (95%CI: 69.4-78.8). The differences between risk classes over the whole observation period was significant (log-rank test: p<0.0001). As regards OS and CSS, low risk level presented a small number of events and the analysis was not reliable. What emerges instead in risk levels intermediate and high is that the type of radiotherapy to which patients are subjected is not statistically significant and so it does not impact on overall and cancer specific survivals. The assessment of acute toxicity revealed a gastrointestinal negative effect of EBRT+ concomitant boost, while the IRT alone showed a low impact in all the examined patterns. Gastrointestinal and haematological acute toxicities resulted statistically significant among the three different risk group levels, increasing with risk level. The incidence of late toxicity was larger in patients treated with EBRT+IRT but no significant statistically differences were observed among the three risk group levels.

Conclusion:

This retrospective study allowed to give a picture of the real national use of adjuvant radio- and systemic therapy for endometrial cancer and to compare them with current guidelines.

External beam and vaginal interventional radiation therapy remain integral aspects of adjuvant therapy for endometrial cancer but molecular study are necessary to personalize the treatment and avoid overtreatment.

Keywords: Endometrial Cancer, radiotherapy

References:

Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma International Journal of Gynecologic Cancer 2021; 31:12-39.

2011

Poster Discussion

Physical & psychosocial effects of radical chemoradiotherapy for cervix cancer: a systematic review

Claire Powlesland 1,2 , Carole Burnett 3,4,5 , Rachel Harris 6 , Georgina Jones 1 , Patricia Holch 1